Core Insights - Merck has showcased its commitment to innovation and health in China for the seventh consecutive year at the China International Import Expo, emphasizing its role in saving lives and improving health outcomes [1] Group 1: Product Offerings - At this year's expo, Merck will display approximately 30 approved drugs and vaccines in China, covering areas such as oncology, anti-infection, diabetes, and rare diseases, including several innovative drugs making their debut [2] - Merck is advancing multiple clinical studies in various therapeutic areas in China and plans to introduce over 40 new products and indications in the next five years [2] Group 2: Vaccines and Cancer Treatment - As a leader in vaccine innovation, Merck has transferred hepatitis B vaccine production technology to China at zero profit since 1989 and has launched multiple antiviral and antibacterial vaccines, protecting over 50 million women with its HPV vaccines [3] - In cancer treatment, Merck's immunotherapy product line is expected to have 32 indications approved in China by August 2025, targeting high-mortality cancers and aiming to create a future where cancer is treatable [3] Group 3: Collaborations and Initiatives - Over the past three years, Merck has engaged in several R&D collaborations with local pharmaceutical companies in areas such as cardiovascular, metabolic, and oncology [3] - The establishment of the Merck China Innovation Cooperation Center (MCICC) on November 1, 2024, aims to enhance collaboration within China's life sciences ecosystem and accelerate the clinical translation of innovative results [3] Group 4: Animal Health and Community Engagement - Merck promotes animal health through its comprehensive product offerings for pets, poultry, pigs, ruminants, and aquaculture, adhering to the principle that "science makes animals healthier" [4] - The company has initiated significant community health projects, including the "Key to Life" cancer immunotherapy patient assistance program and the "VHL Uncommon" patient assistance project, demonstrating its long-term commitment to improving patient accessibility in China [4]

Core Insights - Merck, a global leader in biopharmaceuticals, has showcased its medical innovations and collaborations with local pharmaceutical companies at the 8th China International Import Expo (CIIE) for the seventh consecutive year [1][2] - The company has introduced approximately 30 approved drugs and vaccines in China, covering areas such as oncology, anti-infection, diabetes, and rare diseases, including several innovative drugs making their debut at the expo [1] - Merck plans to introduce over 40 new products and indications to China in the next five years, focusing on breakthrough scientific achievements in various therapeutic areas [1][2] Drug and Vaccine Development - Merck's four-valent and nine-valent HPV vaccines have protected over 50 million women in China and have recently been approved for male use to prevent HPV-related cancers and diseases [2] - In the oncology sector, Merck has a product line centered on tumor immunotherapy, with 32 indications expected to be approved in China by August 2025, targeting high-mortality and difficult-to-treat cancers [2] Collaborations and Innovations - Over the past three years, Merck has engaged in multiple R&D collaborations with five local pharmaceutical companies, including Kelun-Biotech and Hengrui Medicine, focusing on cardiovascular, metabolic, and oncology fields [2] - The establishment of the Merck China Innovation Cooperation Center (MCICC) on November 1, 2024, aims to enhance collaboration within China's life sciences ecosystem and accelerate the clinical translation of innovative results from China [2] Animal Health - At the expo, Merck also presented its products and solutions covering five major business areas in animal health, including pets, poultry, pigs, ruminants, and aquaculture [2]